Pulmonx Corporation – NASDAQ:LUNG
Pulmonx stock price today
$1.53
-5.17
-77.16%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 6 hours
Pulmonx stock price monthly change
-9.70%
month
Pulmonx stock price quarterly change
-9.70%
quarter
Pulmonx stock price yearly change
-48.74%
year
Pulmonx key metrics
Market Cap | 243.64M |
Enterprise value | 333.84M |
P/E | -6.75 |
EV/Sales | 6.22 |
EV/EBITDA | -5.96 |
Price/Sales | 7.66 |
Price/Book | 2.66 |
PEG ratio | 0.37 |
EPS | -1.53 |
Revenue | 72.99M |
EBITDA | -56.68M |
Income | -58.73M |
Revenue Q/Q | 29.71% |
Revenue Y/Y | 27.14% |
Profit margin | -109.8% |
Oper. margin | -109.27% |
Gross margin | 74.29% |
EBIT margin | -109.27% |
EBITDA margin | -77.66% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePulmonx stock price history
Pulmonx stock forecast
Pulmonx financial statements
Average Price Target
$13
Potential upside: 749.67%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 17.19M | -16.19M | -94.19% |
|---|---|---|---|
| Sep 2023 | 17.66M | -14.9M | -84.33% |
| Dec 2023 | 19.27M | -13.88M | -72.04% |
| Mar 2024 | 18.85M | -13.74M | -72.92% |
| Jun 2023 | 193113000 | 59.16M | 30.64% |
|---|---|---|---|
| Sep 2023 | 185016000 | 59.27M | 32.04% |
| Dec 2023 | 178951000 | 60.63M | 33.88% |
| Mar 2024 | 164584000 | 54.08M | 32.86% |
| Jun 2023 | -7.89M | -813K | 92K |
|---|---|---|---|
| Sep 2023 | -8.62M | 987K | 571K |
| Dec 2023 | -8.44M | -2.75M | 17K |
| Mar 2024 | -11.79M | -2.50M | 864K |
Pulmonx alternative data
| Aug 2023 | 269 |
|---|---|
| Sep 2023 | 269 |
| Oct 2023 | 269 |
| Nov 2023 | 269 |
| Dec 2023 | 269 |
| Jan 2024 | 269 |
| Feb 2024 | 269 |
| Mar 2024 | 279 |
| Apr 2024 | 279 |
| May 2024 | 279 |
| Jun 2024 | 279 |
| Jul 2024 | 279 |
Pulmonx other data
23.33%
-67.48%
of LUNG is owned by hedge funds
54
-57
8.65M
-25.11M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 11184 |
| Feb 2024 | 0 | 21184 |
| Mar 2024 | 0 | 16664 |
| Apr 2024 | 0 | 1184 |
| May 2024 | 0 | 1184 |
| Jun 2024 | 0 | 10956 |
| Aug 2024 | 14245 | 0 |
| Sep 2024 | 0 | 30351 |
| Oct 2024 | 0 | 20000 |
| Nov 2024 | 0 | 20000 |
| Dec 2024 | 0 | 9873 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | ROSE GEOFFREY BERAN officer: CHIEF CO.. | Common Stock | 392 | $6.19 | $2,426 | ||
Sale | ROSE GEOFFREY BERAN officer: CHIEF CO.. | Common Stock | 690 | $6.18 | $4,264 | ||
Sale | ROSE GEOFFREY BERAN officer: CHIEF CO.. | Common Stock | 1,756 | $6.19 | $10,870 | ||
Sale | ROSE GEOFFREY BERAN officer: CHIEF CO.. | Common Stock | 1,538 | $6.18 | $9,505 | ||
Sale | LEHMAN DAVID AARON officer: GENERAL .. | Common Stock | 410 | $6.18 | $2,534 | ||
Sale | LEHMAN DAVID AARON officer: GENERAL .. | Common Stock | 722 | $6.19 | $4,469 | ||
Sale | LEHMAN DAVID AARON officer: GENERAL .. | Common Stock | 2,755 | $6.19 | $17,053 | ||
Sale | LEHMAN DAVID AARON officer: GENERAL .. | Common Stock | 1,610 | $6.18 | $9,950 | ||
Sale | FRENCH GLENDON E. III director | Common Stock | 20,000 | $6.63 | $132,600 | ||
Sale | FRENCH GLENDON E. III director | Common Stock | 20,000 | $6.52 | $130,400 |
| Patent |
|---|
Application Filling date: 11 Apr 2022 Issue date: 28 Jul 2022 |
Application Filling date: 16 Mar 2022 Issue date: 30 Jun 2022 |
Application Filling date: 7 Mar 2022 Issue date: 16 Jun 2022 |
Grant Filling date: 5 Jun 2019 Issue date: 3 May 2022 |
Grant Utility: Selective lung tissue ablation Filling date: 2 Oct 2019 Issue date: 19 Apr 2022 |
Grant Utility: Methods and devices for passive residual lung volume reduction and functional lung volume expansion Filling date: 31 May 2019 Issue date: 12 Apr 2022 |
Application Filling date: 3 Aug 2021 Issue date: 10 Feb 2022 |
Application Filling date: 30 Jun 2021 Issue date: 13 Jan 2022 |
Application Filling date: 30 Jun 2021 Issue date: 13 Jan 2022 |
Application Filling date: 2 Jul 2021 Issue date: 28 Oct 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 1 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 21 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 30 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 6 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Glendon E. French (1962) Chief Executive Officer, Pres & Director | $626,820 |
| Mr. Geoffrey Beran Rose (1973) Chief Commercial Officer | $391,520 |
| Mr. David A. Lehman (1961) Gen. Counsel & Sec. | $147,080 |
-
What's the price of Pulmonx stock today?
One share of Pulmonx stock can currently be purchased for approximately $1.53.
-
When is Pulmonx's next earnings date?
Unfortunately, Pulmonx's (LUNG) next earnings date is currently unknown.
-
Does Pulmonx pay dividends?
No, Pulmonx does not pay dividends.
-
How much money does Pulmonx make?
Pulmonx has a market capitalization of 243.64M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 27.98% to 68.68M US dollars.
-
What is Pulmonx's stock symbol?
Pulmonx Corporation is traded on the NASDAQ under the ticker symbol "LUNG".
-
What is Pulmonx's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Pulmonx?
Shares of Pulmonx can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Pulmonx's key executives?
Pulmonx's management team includes the following people:
- Mr. Glendon E. French Chief Executive Officer, Pres & Director(age: 63, pay: $626,820)
- Mr. Geoffrey Beran Rose Chief Commercial Officer(age: 52, pay: $391,520)
- Mr. David A. Lehman Gen. Counsel & Sec.(age: 64, pay: $147,080)
-
How many employees does Pulmonx have?
As Jul 2024, Pulmonx employs 279 workers.
-
When Pulmonx went public?
Pulmonx Corporation is publicly traded company for more then 4 years since IPO on 1 Oct 2020.
-
What is Pulmonx's official website?
The official website for Pulmonx is pulmonx.com.
-
Where are Pulmonx's headquarters?
Pulmonx is headquartered at 700 Chesapeake Drive, Redwood City, CA.
-
How can i contact Pulmonx?
Pulmonx's mailing address is 700 Chesapeake Drive, Redwood City, CA and company can be reached via phone at +65 03640400.
-
What is Pulmonx stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Pulmonx in the last 12 months, the avarage price target is $13. The average price target represents a 749.67% change from the last price of $1.53.
Pulmonx company profile:
Pulmonx Corporation
pulmonx.comExchange:
NASDAQ
Full time employees:
279
Industry:
Medical - Devices
Sector:
Healthcare
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
700 Chesapeake Drive
Redwood City, CA 94063
Redwood City, CA 94063
CIK: 0001127537
ISIN: US7458481014
CUSIP: 745848101
